ClinicalTrials.gg
RecruitingNCT05681026Updated Feb 27, 2026

Cultural Tailoring and Pilot Testing of an Inpatient Yoga Therapy Program for Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation in India, Tanzania, and the United States

An interventional study of Yoga Sessions and Questionnaries in Hematopoietic Stem Cell Transplantation and Cancer, sponsored by M.D. Anderson Cancer Center. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

To develop and measure the effects of a culturally sensitive yoga program for inpatients

Read the detailed description

Primary Objective:

1. To develop a culturally tailored yoga therapy (YT) program for HSCT patients. We will conduct semi-structured interviews with patients from each center to examine cultural norms, culturally sensitive language, and specific factors relevant to yoga and psychosocial support.

Secondary Objectives:

  1. To optimize the HSCT YT program using an iterative process. Fifteen patients from each center (or until thematic saturation based on exit interviews) will participate in the yoga program two weeks prior to the transplant and throughout the first 30 days of the HSCT. Sessions will be delivered in person, via telehealth (Zoom), or in combination.
  2. To examine the feasibility of adherence and follow-up completion. We will declare the intervention feasible if: (a) at least 50% of patients complete a minimum of 50% of the 12 YT sessions, and (b) at least 60% of participants complete follow-up measures at 2 months after transplant (± 7 days).
02

Conditions studied

  • Hematopoietic Stem Cell Transplantation
  • Cancer

Browse trials for

03

In context

Neoplasms

10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's planned enrollment of 60 is close to the median of 60 across 7,703 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 3,047 studies on the registry; 578 are open to participants now.

Of its 612 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Cancer patients scheduled to undergo an or allogeneic HSCT at MD Anderson, HCG, or MNH;
  2. Age 18 or older;
  3. English, Hindi, or Swahili speaking;
  4. Able to sign a written and be willing to follow protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Extreme mobility issues that preclude participating in the YT;
  • Major thought disorders such as schizophrenia or uncontrolled bipolar disorder;
  • HCT comorbidity score of 3 or higher, excluding cancer diagnoses
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Yoga Sessions

    Participants will take part in Yoga of gentle movements, breathing exercises, relaxation techniques, and meditation all tailored to the participant's needs.

    Behavioral: Yoga Sessions · Behavioral: Questionnaries · Behavioral: Interviews

Interventions

  • BehavioralYoga Sessions

    Participants will have up to 12 sessions, 3 sessions per week starting two weeks before the transplant and throughout the first 30 days of your hospitalization.

  • BehavioralQuestionnaries

    Participants will complete 4 questionnaires about any symptoms you may be having, any anxiety and/or depression you may be having, your quality of life, and your expectations about your treatment.

  • BehavioralInterviews

    Participants will have an exit interview last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom, FaceTime, or other approved video call methods.). The interview will be audio and video recorded and transcribed (typed).

06

What researchers measure

Primary outcomes

  1. Patient Health Questionnaire-8 (PHQ-8)

    The PHQ-8 is a 8-item self-report questionnaire used to assess bother of depressive symptoms over the past 2 weeks. The PHQ-8 is a 8-item questionnaire to screen for degree of depressive symptoms scored on a 0-24 scale with higher scores indicating greater distress and impairment

    Time frame: through study completion; an average of 1 year

07

Study locations

3 of 3 sites recruiting
  • M D Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Lorenzo Cohen, PHD · Contactlcohen@mdanderson.org · 713-745-4260
    • Lorenzo Cohen, PHD · Principal investigator
  • Swami Vivekananda Yoga Anusandhana Samsthana
    Giddenahalli, Karnataka 560105, India
    Recruiting
    • Manjunath Sharma, PhD · Contactnkmsharma@svyasa.org · +91-080-22639983
    • Manjunath Sharma, PhD · Principal investigator
  • Muhimbili National Hospital
    Dar es Salaam, Tanzania
    Recruiting
    • Stella Rwezaula, MD · Contactstarwezy@yahoo.com · +255-22-2151367-9
    • Stella Rwezaula, MD · Principal investigator
08

References and documents

Publications

  • Mallaiah S, Majumdar V, Mama SK, Olson AL, Daher M, Badgare Y, Kolar Srinivasrao N, Rwezaula S, Muhoka P, Rao R, Jadav S, Wagner R, Wilson A, Nandi Krishnamurthy M, Cohen L. Adapting Yoga Therapy to Meet the Needs of Inpatients Undergoing Hematopoietic Stem Cell Transplantation: Insights From an International, Multisite, Qualitative Study. JCO Glob Oncol. 2026 Mar;12(3):e2500567. doi: 10.1200/GO-25-00567. Epub 2026 Mar 6. PubMed 41791008 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Jan 2028, 53 months after the start.

Of 1,981 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 53 months is above that.

Counting every sponsor, half of 2,056 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2022
First posted
Jan 11, 2023
StartActual
Aug 28, 2023
Primary completionEst.
Jan 31, 2028
CompletionEst.
Jan 31, 2028
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05681026
Responsible party
Sponsor
First posted
Jan 11, 2023
Start date
Aug 28, 2023
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Feb 27, 2026

Study contacts

Lorenzo Cohen, PHD
Contact
lcohen@mdanderson.org
(713) 745-4260
Lorenzo Cohen, PHD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion